Plasma inflammatory cytokines and survival of pancreatic cancer patients. by Babic, A. et al.
Thomas Jefferson University
Jefferson Digital Commons
Department of Medical Oncology Faculty Papers Department of Medical Oncology
4-1-2018
Plasma inflammatory cytokines and survival of
pancreatic cancer patients.
A. Babic
Dana-Farber Cancer Institute
N. Schnure
University of Pennsylvania
N. P. Neupane
Thomas Jefferson University
M. M. Zaman
Beth Israel Deaconess Medical Center
N. Rifai
Boston Children's Hospital
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/medoncfp
Part of the Gastroenterology Commons, and the Oncology Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please
contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Babic, A.; Schnure, N.; Neupane, N. P.; Zaman, M. M.; Rifai, N.; Welch, M. W.; Brais, L. K.;
Rubinson, D. A.; Morales-Oyarvide, V.; Yuan, C.; Zhang, S.; Poole, E. M.; Wolpin, B. M.; Kulke, M.
H.; Barbie, D. A.; Wong, K.; Fuchs, C. S.; and Ng, K., "Plasma inflammatory cytokines and survival
of pancreatic cancer patients." (2018). Department of Medical Oncology Faculty Papers. Paper 79.
https://jdc.jefferson.edu/medoncfp/79
Authors
A. Babic, N. Schnure, N. P. Neupane, M. M. Zaman, N. Rifai, M. W. Welch, L. K. Brais, D. A. Rubinson, V.
Morales-Oyarvide, C. Yuan, S. Zhang, E. M. Poole, B. M. Wolpin, M. H. Kulke, D. A. Barbie, K. Wong, C. S.
Fuchs, and K. Ng
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/medoncfp/79
Babic et al. Clinical and Translational Gastroenterology  (2018) 9:145 
DOI 10.1038/s41424-018-0008-5 Clinical and Translational Gastroenterology
OR IG INAL CONTR IBUT ION Open Ac ce s s
Plasma inﬂammatory cytokines and
survival of pancreatic cancer patients
A. Babic, PhD1, N. Schnure, MD2, N. P. Neupane, MS3, M. M. Zaman, PhD4, N. Rifai, PhD5, M. W. Welch, BS1,
L. K. Brais, MPH1, D. A. Rubinson, MD, PhD1, V. Morales-Oyarvide, MD, MPH1, C. Yuan, MS1, S. Zhang, MS1,
E. M. Poole, PhD6, B. M. Wolpin, MD, MPH1, M. H. Kulke, MD1, D. A. Barbie, MD1, K. Wong, MD, PhD1,
C. S. Fuchs, MD, MPH7 and K. Ng, MD, MPH1
Abstract
Objectives: Inﬂammation and inﬂammatory conditions have been associated with pancreatic cancer risk and
progression in a number of clinical, epidemiological, and animal model studies. The goal of the present study is to
identify plasma markers of inﬂammation associated with survival of pancreatic cancer patients, and assess their joint
contribution to patient outcome.
Methods: We measured circulating levels of four established markers of inﬂammation (C-reactive protein (CRP),
interleukin-6 (IL-6), soluble tumor necrosis factor receptor type II (sTNF-RII), and macrophage inhibitory cytokine-1
(MIC-1)) in 446 patients enrolled in an ongoing prospective clinic-based study. Hazard ratios (HRs) and 95% conﬁdence
intervals (CI) for death were estimated using multivariate Cox proportional hazards models.
Results: Overall mortality was signiﬁcantly increased in patients in the top quartile of CRP (HR= 2.52, 95% CI:
1.82–3.49), IL-6 (HR= 2.78, 95% CI: 2.03–3.81), sTNF-RII (HR= 2.00, 95% CI: 1.46–2.72), and MIC-1 (HR= 2.53, 95% CI:
1.83–3.50), compared to those in the bottom quartile (P-trend <0.0001 for all four comparisons). Furthermore, patients
with higher circulating concentrations of all four cytokines had a median survival of 3.7 months; whereas, those with
lower levels had a median survival of 19.2 months (HR= 4.55, 95% CI: 2.87–7.20, P-trend <0.0001).
Conclusion: Individual elevated plasma inﬂammatory cytokines are associated with signiﬁcant and dramatic
reductions in pancreatic cancer patient survival. Furthermore, we observed an independent combined effect of those
cytokines on patient survival, suggesting that multiple inﬂammatory pathways are likely involved in PDAC progression.
Future research efforts to target the inﬂammatory state using combination strategies in pancreatic cancer patients are
warranted.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the fourth
leading cause of cancer death in the US, with a 5-year
survival rate of only 8%1. Several pathologic character-
istics obtained at surgery, such as tumor size, resection
margin, and number of involved lymph nodes have been
associated with reduced survival2. However, only 15–20%
of PDAC patients are able to undergo resection3. Con-
sequently, identiﬁcation of additional biomarkers that can
be easily assayed in all patients is urgently needed for
elucidation of underlying mechanisms of disease pro-
gression and development of new therapeutic strategies.
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Numerous studies have suggested a role of inﬂamma-
tion in pancreatic cancer development and progression4.
Cytokines synthesized by the host, tumor cells, and stro-
mal cells play a role in cellular proliferation, angiogenesis,
and metastasis5,6. Furthermore, epidemiological studies
reveal an association between several inﬂammation-
associated conditions, such as diabetes7 and obesity8,
with PDAC survival, further implicating inﬂammation in
PDAC pathogenesis.
Elevated levels of individual inﬂammatory markers,
including C-reactive protein (CRP), interleukine-6 (IL-6),
macrophage inhibitory cytokine-1 (MIC-1), and tumor
necrosis factor-α (TNF-α), as well as combined scores, such
as the Glasgow Prognostic Score (GPS), or CRP to albumin
ratio, have been associated with decreased survival in PDAC
patients9–24. However, these studies were small and often
did not account for potential confounding variables.
Moreover, it is not known to what extent these inﬂamma-
tory pathways, which have distinct roles in tumor devel-
opment, such as cell proliferation, invasion, angiogenesis,
and immune evasion5,6 might be involved in disease pro-
gression and patient survival. We therefore evaluated the
individual and combined association of these four markers
of inﬂammation with patient survival in a large prospective
study of well-characterized PDAC patients.
Materials and methods
Study population
Patients were drawn from an ongoing clinic-based study
at the Dana-Farber Cancer Institute (DFCI; Boston, MA).
All new patients with a diagnosis of PDAC who were seen
in the DFCI Gastrointestinal Cancer Center outpatient
clinic were prospectively identiﬁed and enrolled to this
cohort study between December 22, 2004 and June 16,
2014. Patients were eligible for the study if they had
pathologically conﬁrmed PDAC and were age 21 or older.
The study was approved by the Dana-Farber/Harvard
Cancer Center Institutional Review Board. All partici-
pants provided informed consent for their biological
specimens and clinical data to be used for research.
Pancreatic cancer cases
A total of 1,038 DFCI patients were approached for
consent between December 22, 2004 and June 18, 2014,
and 743 (72%) agreed to participate (Supplementary Fig-
ure 1). Of patients that provided consent, 485 completed a
questionnaire on medical history, medication use, life-
style, and family history. There were no differences
between patients who did or did not complete the ques-
tionnaire in regards to gender, age at diagnosis, race/
ethnicity, or stage at diagnosis. Of the 485 patients who
completed the questionnaire, 450 patients provided blood
samples at an average of 1.4 months after diagnosis
(Table 1). We excluded patients with missing information
Table 1 Baseline characteristics of pancreatic cancer
patients included in the study
Characteristics Pancreatic cancer cases (N
= 446)
Mean (SD)
Age at blood draw, years 64.1 (10.4)
BMI, kg/m2 29.6 (74.2)
Physical activity, MET-hr/wk 14.3 (25.1)
Median (SD)
Time between diagnosis and blood
draw, months
1.4 (7.6)
Time between blood draw and survey,
months
0 (2.6)
Time between surgery and blood draw,
monthsa
1.6 (5.3)
Number of metastatic sitesb 1.0 (0.7)
CA19-9 at blood draw, U/ml 644 (274,892)
Gender, No. (%)
Female 211 (47)
Male 235 (53)
Diabetes, No. (%)
No 279 (63)
Yes 141 (32)
Unknown 26 (6)
Cancer stage, No. (%)
Localized 12 (3)
Locally advanced 100 (22)
Metastatic 271 (61)
No. of evidence of disease 63 (14)
Grade, No. (%)
Well/moderately differentiated 84 (19)
Poorly differentiated/undifferentiated 96 (22)
Unknown 266 (60)
Smoking status at blood draw, No. (%)
Never 194 (44)
Former 216 (48)
Current 32 (7)
Unknown 4 (1)
Regular aspirin use at blood drawc, No. (%)
No 145 (33)
Yes 142 (32)
Unknown 159 (36)
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about height (n= 1), gender (n= 1), unknown stage at the
time of blood draw (n= 1), and missing inﬂammatory
cytokine data (n= 1).
Exposure assessment
CRP, MIC-1, and sTNF-RII were assayed in the
laboratory of Dr. Nader Rifai (Boston Children’s Hospital,
Boston, MA). The sTNF-RII is an established surrogate
measurement for TNF-α due to its role in TNF-α sig-
naling, lower diurnal variation, and increased stability in
frozen plasma25,26. Furthermore, unlike TNF-α levels of
which tend to ﬂuctuate, levels of sTNF-RII are stable over
long periods of time27. CRP was measured using an
immunoturbidimetric assay (Roche Diagnostics, Indiana-
polis, IN), with a limit of detection of 0.03 mg/L. MIC-1
and sTNF-RII were measured by an ELISA assay (R&D
Systems, Minneapolis, MN), with a sensitivity of 4.36 pg/
mL for MIC-1 and 0.6 pg/mL for sTNF-RII. IL-6 was
measured as part of the 16-plex pro- and anti-
inﬂammatory cytokine panel (Human Cytokine A
Premixed Magnetic Luminex Performance Assay, R&D
Systems, Minneapolis, MN). The sensitivity of the assay is
1.11 pg/mL. Coefﬁcients of variation for each assay were
calculated using 10% blinded duplicate samples, and
ranged from 2.5% for CRP to 6.1% for sTNF-RII.
Laboratory personnel was blinded to patient status.
Covariate assessment
Data on patient and disease characteristics, such as
age at time of blood draw, albumin levels, gender, body
mass index (BMI) at time of blood draw, date of diag-
nosis, stage, treatment history, and date of death were
extracted from the medical record. Information on race,
smoking status, physical activity, and aspirin and non-
steroidal anti-inﬂammatory drug (NSAID) use at time of
blood draw were extracted from the self-administered
questionnaire. GPS was calculated as previously
described9,24.
Statistical analysis
All inﬂammatory cytokines were log-transformed to
improve normality. Correlation between cytokines was ana-
lyzed using Spearman correlation. We used the Wilcoxon
rank-sum or Kruskal–Wallis test to evaluate differences in
cytokine levels between two or more groups of interest.
We used the Cox proportional hazards model to eval-
uate the hazards ratios (HRs) and 95% conﬁdence inter-
vals (CIs) for mortality. Person-time was calculated as
time between blood collection and death or last follow-up
(November 16, 2016). To test the proportionality of
hazards assumption, we evaluated the cross product of
time and inﬂammatory cytokines. This test revealed a
violation of the proportionality of hazards assumption
which was addressed by including an interaction term
between time and cytokine levels in the models, allowing
calculation of HRs for different time points. Inﬂammatory
cytokines were modeled as quartiles. To evaluate the
trend of the association between inﬂammatory cytokines
and survival across quartiles, we used the median of each
quartile as a continuous variable in the model. In multi-
variate models, we adjusted a priori for age at blood col-
lection, gender, grade (well differentiated, moderately
differentiated, poorly differentiated, undifferentiated,
unknown), cancer stage (localized/no evidence of disease,
locally advanced, metastatic), treatment status (treatment
naive, on treatment, post treatment), number of meta-
static sites, BMI (continuous), and physical activity (con-
tinuous) at time of blood collection. We additionally
examined potential confounding by smoking, aspirin use,
NSAID use, and diabetes status at time of blood
collection.
To investigate whether the combination of cytokine
concentrations is more strongly related to mortality than
each individual cytokine alone, we also evaluated the
association between a combined inﬂammatory cytokine
score and mortality. We calculated this combined score
by summing the number of cytokines with levels above
the population median. The score therefore ranged from 0
(no cytokines above the median) to 4 (all four cytokine
levels above the median).
To compare discrimination between different survival
models, we calculated the overall C-index. This metric is
an extension of the receiver operating characteristic for
the Cox proportional hazard model28.
We performed subgroup analyses to examine potential
effect modiﬁcation by age (<median of 64.5 years, ≥64.5
years), gender, BMI (<25 kg/m2, ≥25 kg/m2), diabetes (yes
vs. no), smoking status (never vs. ever smoker), regular
aspirin use (yes vs. no), grade of differentiation (well/
moderately vs. poorly differentiated/undifferentiated), and
metastatic status (non-metastatic vs. metastatic). We also
performed a stratiﬁed analysis by treatment status (treat-
ment naive vs. on/post treatment) for metastatic patients
Table 1 continued
Characteristics Pancreatic cancer cases (N
= 446)
Treatmentd status at time of blood draw, No. (%)
Treatment naive 234 (53)
On treatment 164 (37)
Post treatment 48 (11)
SD standard deviation, BMI body mass index, MET-hr metabolic equivalent of
task-hour
aAmong patients who underwent surgical resection
bAmong patients with metastatic disease
cRegular use is deﬁned as intake frequency of≥3 days/week
dIncludes chemotherapy and radiation
Babic et al. Clinical and Translational Gastroenterology  (2018) 9:145 Page 3 of 12
Ofﬁcial journal of the American College of Gastroenterology
Table 2 Plasma inﬂammatory biomarkers according to selected patient and tumor characteristics
Characteristics CRP (mg/L) (n=
437) median (IQ
range)
P-valueb IL-6 (pg/mL) (n
= 427) median
(IQ range)
P-valueb sTNF-RII (pg/mL)
(n= 423) median
(IQ range)
P-valueb MIC-1 (pg/mL) (n
= 434) median
(IQ range)
P- Valueb
Agea
<64.5 years 8.1 (24.9) 2.6 (2.4) 3443.9 (2060.2) 1698.2 (1819.5)
≥64.5 years 7.3 (20.6) 0.47 3.0 (2.2) 0.19 3726.6 (2390.5) 0.01 2064.8 (1931.4) 0.005
Time between diagnosis and blood drawa
<1.4 months 10.8 (24.2) 2.8 (2.4) 3508.0 (2309.6) 1719.5 (1689.2)
≥1.4 months 5.4 (17.7) 0.002 2.8 (2.2) 0.29 3730.7 (1890.7) 0.07 1995.0 (1938.5) 0.01
BMIa
<25.3 kg/m2 5.4 (18.7) 2.6 (1.8) 3531.7 (2619.3) 1837.2 (1824.2)
≥25.3 kg/m2 12.1 (24.0) <0.0001 3.0 (2.4) 0.001 3641.2 (2619.3) 0.30 1938.2 (2002.4) 0.41
Physical activitya
<3.9 MET-hr/wk 7.4 (24.4) 2.9 (2.4) 3512.2 (2213.7) 2055.1 (2039.1)
≥3.9 MET-hr/wk 6.7 (25.5) 0.87 2.5 (1.7) 0.71 3606.8 (1827.2) 0.29 1937.0 (1413.4) 0.40
Gender
Male 9.5 (24.5) 2.8 (2.6) 3660.3 (2015.4) 2022.5 (2462.1)
Female 7.2 (18.7) 0.13 2.8 (1.8) 0.87 3493.4 (2395.8) 0.59 1773.4 (1656.8) 0.03
Diabetes
No 7.4 (20.6) 2.8 (2.2) 3547.0 (2174.2) 1819.2 (1744.2)
Yes 9.0 (26.9) 0.44 2.8 (2.3) 0.92 3644.6 (2129.6) 0.41 2221.1 (2811.6) 0.01
Cancer stage
Localized 4.5 (10.3) 1.8 (2.1) 3490.5 (2103.0) 1443.1 (1397.0)
Locally advanced 4.9 (16.0) 2.8 (1.9) 3290.3 (1827.9) 1727.1 (1924.3)
Metastatic 12.6 (30.5) 2.8 (2.5) 3803.6 (2182.2) 2165.3 (1991.8)
NED 2.9 (8.5) <0.0001 2.7 (2.3) 0.14 3497.0 (1973.2) 0.05 1390.7 (901.5) <0.0001
Grade
Well/moderately
differentiated
4.1 (15.3) 2.7 (2.4) 3112.0 (1454.8) 1575.3 (1529.7)
Poorly differentiated/
undifferentiated
11.1 (31.3) 0.01 3.0 (2.7) 0.16 3944.5 (2586.0) 0.005 1975.2 (1846.0) 0.09
Smoking
Never 8.0 (21.8) 2.8 (2.2) 3570.1 (2040.3) 1877.2 (1943.7)
Past 7.8 (23.0) 2.8 (2.5) 3714.3 (2070.0) 1949.8 (2034.3)
Current 11.7 (22.4) 0.55 2.8 (2.9) 0.39 3569.5 (1722.8) 0.30 1734.6 (2031.2) 0.85
Regular aspirin usec
Non-users 5.5 (24.0) 2.5 (1.6) 3509.2 (1826.6) 1869.3 (1451.4)
Users 10.6 (22.9) 0.09 3.0 (2.5) 0.01 3768.1 (2708.8) 0.03 2180.8 (2586.0) 0.04
Regular NSAID usec
Non-users 6.6 (25.0) 2.8 (2.2) 3661.9 (2090.5) 2064.8 (1746.5)
Users 8.9 (34.2) 0.21 2.8 (1.5) 0.96 3522.4 (1950.8) 0.59 1769.7 (1344.3) 0.44
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only. Statistical interaction was evaluated by including a
cross-product term containing the stratiﬁcation variable
and inﬂammatory cytokine level (as quartiles) into the
model and performing the likelihood ratio test.
Kaplan–Maier method and log-rank tests were used to
illustrate and analyze survival curves. Statistical analyses
were performed using SAS software (version 9.4; SAS
Institute, Cary, NC). All P-values were two-sided.
Results
Characteristics of the study population are shown in
Table 1. The study included 211 female (47%) and 235
(53%) male participants. The mean age at diagnosis was
64.1 years. At the time of blood draw, 3% of patients had
localized disease, 22% had locally advanced disease, 61%
had metastatic disease, and 14% of patients had no evi-
dence of disease following surgical resection. Most
patients (53%) were treatment naive at the time of blood
draw, 37% were on active treatment with chemotherapy
and/or radiation, and 11% were post treatment.
Median survival time in the entire patient cohort was
9.7 months (30.1 months for patients with no evidence of
disease following surgical resection, 19.3 months with
patients with localized disease, 12.4 months for those with
locally advanced tumors, and 6.5 months for those with
metastatic disease). Median follow-up was 9.3 months; at
last follow-up, 413 patients (92.6%) had died.
We observed signiﬁcant, but weak to moderate, corre-
lations between cytokines, with correlation coefﬁcients
ranging from 0.12 (IL-6 and sTNF-RII) to 0.41 (MIC-1
and sTNF-RII) (Supplementary table 1). CRP levels dif-
fered signiﬁcantly by time between diagnosis and blood
draw, BMI, stage, and grade (Table 2). IL-6 levels were
higher in regular aspirin users and patients with higher
BMI. sTNF-RII levels were higher among older patients
and patients with poorly differentiated and undiffer-
entiated tumors. MIC-1 levels differed signiﬁcantly by age,
gender, time between diagnosis and blood draw, cancer
stage, presence of diabetes, aspirin use, and treatment
status.
For each measured cytokine, patients with levels in
the highest quartile had signiﬁcantly worse survival
(log-rank P-value <0.0001) (Fig. 1a–d). In the multi-
variate model, compared to patients in the lowest
quartile, the mortality hazard of patients in the highest
quartiles at the median survival time of 9.5 months
was 2.52 (95% CI: 1.82–3.49) for CRP, 2.78
(95% CI: 2.03–3.81) for IL-6, 2.00 (95% CI: 1.46–2.72)
for sTNF-RII, and 2.53 (95% CI: 1.83–3.50) for MIC-1
(Table 3). Moreover, there was a signiﬁcant linear trend
across quartiles (P-trend <0.0001 for all four cytokines).
Further adjustment for diabetes, smoking, aspirin use,
and non-aspirin NSAID use did not alter the associa-
tions (data not shown). We observed similar HRs for
death across cytokine quartiles at 6 and 12 months
(Supplementary Tables 2 and 3).
We also examined the association between CRP levels
and mortality using the conventional CRP cutoff of 10
mg/L. Compared to patients with CRP ≤ 10mg/L, those
with CRP >10mg/L had a twofold increase in the risk of
death (multivariate HR: 2.00, 95% CI: 1.62–2.47). When
simultaneously adjusting for all four cytokines in the
multivariate model, we observed a continued signiﬁcant
mortality hazard for patients in the highest quartile of
CRP (HR: 1.59, 95% CI: 1.07–2.37), IL-6 (HR: 1.80, 95%
CI: 1.23–2.65), and MIC-1 (HR: 1.80, 95% CI: 1.22–2.67),
while the association between sTNF-RII and survival was
no longer signiﬁcant (HR: 1.10, 95% CI: 0.75–1.59).
Compared to patients with an inﬂammatory score of 0
and median survival 19.2 months, those with a score of 4
had a median survival of only 3.7 months and adjusted HR
of 4.55 (95% CI: 2.87–7.20; P-trend <0.0001) (Table 4,
Fig. 1e).
The model including CRP had a discriminatory index of
0.80 (95% CI: 0.71–0.88), comparable to those of GPS (C-
index= 0.76, 95% CI: 0.66–0.85) and CRP to albumin
Table 2 continued
Characteristics CRP (mg/L) (n=
437) median (IQ
range)
P-valueb IL-6 (pg/mL) (n
= 427) median
(IQ range)
P-valueb sTNF-RII (pg/mL)
(n= 423) median
(IQ range)
P-valueb MIC-1 (pg/mL) (n
= 434) median
(IQ range)
P- Valueb
Treatment statusd
Treatment naive
On/post treatment 8.8 (21.1) 2.8 (2.1) 3529.3 (2182.0) 1672.5 (1611.1)
6.9 (23.7) 0.74 2.8 (2.2) 0.11 3700.3 (2082.3) 0.53 2145.8 (2580.3) <0.0001
CRP, C-reactive protein; IL-6, interleukin-6; MIC-1, macrophage inhibitory cytokine-1; sTNF-RII, tumor necrosis factor receptor 2; IQ, interquartile range; BMI, body mass
index; MET-hr, metabolic equivalent of task-hour; NED, no evidence of disease, NSAID, nonsteroidal anti-inﬂammatory drug
aCut point determined by the median value
bCalculated using Wilcoxon rank-sum, or Kruskal–Wallis test
cRegular use is deﬁned as intake frequency of ≥3 days/week
dIncludes chemotherapy and radiation
Bold value denote signiﬁcance P-value ≤ 0.05
Babic et al. Clinical and Translational Gastroenterology  (2018) 9:145 Page 5 of 12
Ofﬁcial journal of the American College of Gastroenterology
Fig. 1 Patient survival by quartiles of inﬂammatory cytokines. A combined inﬂammatory score was created by adding number of inﬂammatory
markers with the value above the population median
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ratio (C-index= 0.74, 95% CI: 0.64–0.83) (Supplementary
Tables 4 and 5).
The signiﬁcant association between increasing cytokine
levels and worse mortality was consistent across most
subgroups of known prognostic characteristics (Table 5).
We observed a signiﬁcant interaction between CRP and
BMI (P-interaction= 0.03), and between CRP and aspirin
use (P-interaction= 0.001), with association with worse
mortality being stronger among patients with BMI ≤25
kg/m2 and among aspirin users.
To evaluate whether higher levels of inﬂammatory
cytokines simply reﬂect a greater burden of disease, we
adjusted for disease stage, number of metastatic sites and
CA19-9 levels in the multivariate model and observed no
Table 3 Hazard ratiosa for death by inﬂammatory biomarker levels
HR (95% CI)
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-trendc
CRP (N= 437)
Range (mg/L) 0.05–2.34 2.35–7.72 7.81–24.26 24.42–183.74
Person-months 2356 1616 1376 865
Cases/deaths 109/97 109/101 110/100 109/106
Median OS, months 16.6 10.7 8.4 4.3
Age-adjusted 1.00 (Ref) 1.66 (1.22–2.27) 1.98 (1.45–2.71) 3.28 (2.40–4.49) <.0001
Multivariate-adjustedb 1.00 (Ref) 1.48 (1.08–2.04) 2.08 (1.52–2.86) 2.52 (1.82–3.49) <.0001
IL-6 (N= 427)
Range (pg/ml) 0.17–1.86 1.89–2.76 2.78–4.15 4.17–165.73
Person-months 1905 1791 1299 1030
Cases/deaths 105/95 104/95 110/102 108/103
Median OS, months 14.8 12.1 8.4 4.9
Age-adjusted 1.00 (Ref) 1.18 (0.86–1.62) 1.83 (1.35–2.48) 2.41 (1.78–3.26) <.0001
Multivariate-adjustedb 1.00 (Ref) 1.11 (0.80–1.54) 2.22 (1.62–3.03) 2.78 (2.03–3.81) <.0001
sTNF-RII (N= 423)
Range (pg/ml) 989.36–2655.95 2657.81–3591.33 3606.79–4771.55 4825.31–9918.17
Person-months 1811 1938 1300 1107
Cases/deaths 105/90 106/97 106/104 106/100
Median OS, months 12.5 12.8 8.1 7.0
Age-adjusted 1.00 (Ref) 1.05 (0.77–1.43) 1.59 (1.18–2.14) 1.90 (1.41–2.56) <.0001
Multivariate-adjustedb 1.00 (Ref) 1.05 (0.76–1.45) 1.44 (1.06–1.94) 2.00 (1.46–2.72) <.0001
MIC-1 (N= 434)
Range (pg/ml) 344.40–1215.34 1216.57–1896.73 1897.19–3172.78 3183.01–31829.82
Person-months 2021 2054 1119 999
Cases/deaths 108/95 109/98 109/104 108/104
Median OS, months 14.1 13.2 7.6 4.9
Age-adjusted 1.00 (Ref) 1.20 (0.87–1.64) 2.30 (1.69–3.12) 2.61 (1.91–3.56) <.0001
Multivariate-adjustedb 1.00 (Ref) 1.34 (0.97–1.86) 2.06 (1.50–2.84) 2.53 (1.83–3.50) <.0001
CRP, C-reactive protein; IL-6, interleukin-6; MIC-1, macrophage inhibitory cytokine-1; sTNF-RII, tumor necrosis factor receptor 2. OS, overall survival. HR, hazard ratio. CI,
conﬁdence interval
aHazard ratios at the median survival time of our cohort (9.5 months)
bAdjusted for age at blood draw, gender, grade (well differentiated, moderately differentiated, poorly differentiated, undifferentiated, and unknown), stage (localized/
no evidence of disease, locally advanced, and metastatic), treatment status (naive, on, and post), number of metastatic sites, and BMI (continuous) at blood draw and
physical activity (continuous)
cP-trend values calculated by entering quartile medians as continuous variables in Cox proportional hazards model
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signiﬁcant change of the estimate. In addition, associa-
tions were similar by metastatic disease and number of
metastatic sites (P-interaction >0.25) (Table 5).
Discussion
In this large prospective clinic-based study of 446 PDAC
patients, subjects with higher levels of each of CRP, IL-6,
and MIC-1 experienced a signiﬁcant increase in overall
mortality. Moreover, patients with elevations of all four
markers combined had the largest comparative increase in
mortality, suggesting involvement of multiple activated
inﬂammatory pathways in PDAC progression. Compared
to patients with all cytokines below the population med-
ian, those with all four cytokines above the population
median had an almost ﬁvefold increased hazard of death,
with median survival of 4 vs. 19 months. These associa-
tions were independent of known prognostic factors, such
as tumor stage, grade, number of metastatic sites, and
CA19-9 levels. Furthermore, except for sTNF-RII, the
effects of these cytokines on survival are mutually
independent.
The inverse associations of CRP and IL-6 with patient
survival in our study are consistent with previously
reported ﬁndings10,12,13,19,20,22,23. We further showed
that the associations of these two cytokines are inde-
pendent from each other, as well as from MIC-1 and
sTNF-RII. While we observed a signiﬁcant association
between survival and sTNF-RII, a surrogate for TNF-α,
the association was attenuated after adjusting for CRP,
IL-6 and MIC-1. This therefore argues against an inde-
pendent effect of TNF-α on survival, as has been pre-
viously suggested11. Our ﬁnding of decreased survival
among patients in the top quartile of MIC-1 compared
to those in the lowest quartile is also consistent with
previous studies29,30; however, distinct from those prior
studies, we were able to comprehensively adjust for
potential confounders. We also found that the inﬂuence
of high-MIC-1 levels was independent of CRP, IL-6, and
sTNF-RII. To our knowledge, no previous studies have
assessed the combined contribution of those four
inﬂammatory cytokines on PDAC patient survival.
Several explanations have been proposed to address the
relationship between inﬂammatory cytokines and survival.
High levels of circulating cytokines may result from the
systemic response of host to tumor, reﬂecting the tumor
burden. CRP is produced by the liver as part of the acute
phase response31, and its levels correlate with cancer
progression13,20,22,23. However, adjusting for clinical
markers of aggressive disease did not change our obser-
vation. Moreover, in stratiﬁed analyses the associations
between inﬂammatory cytokines and patient mortality
were similar across subgroups of tumor burden.
Extensive experimental evidence supports the impor-
tance of inﬂammatory cytokines in tumor growth and
progression, both by acting directly on tumor cells and
by modifying the tumor microenvironment5. IL-6 exerts
its protumorigenic effects by activating several signaling
pathways involved in PDAC, such as JAK-STAT3, Ras-
MAPK, and PI3K-Akt, leading to increased cellular
proliferation, angiogenesis, and metastatic potential32.
IL-6 is one of the key factors in the development of
muscle wasting, or cachexia33, which is responsible for
about one third of PDAC-associated deaths and
decreased response to treatment34. Furthermore, it was
shown that IL-6 leads to formation of desmoplastic
stroma35, a dense extracellular matrix which acts as a
physical barrier for effective drug delivery36. MIC-1, a
member of the human transforming growth factor
(TGF)-β superfamily, has both anti- and protumorigenic
roles in colon, breast, prostate, and melanoma cancers37.
Table 4 Hazard ratiosa for death by combined inﬂammatory marker score
Inﬂammatory scoreb
HR (95% CI)
0 1 2 3 4 P-trendc
Person-months 1765 1790 1240 959 460
Cases/deaths 74/65 103/90 94/88 94/92 71/68
Median OS, months 19.2 13.8 7.6 6.5 3.7
Age-adjusted 1.00 (Ref) 1.73 (1.16–2.57) 2.39 (1.60–3.56) 3.36 (2.25–5.03) 4.53 (2.90–7.09) <.0001
Multivariate-adjustedd 1.00 (Ref) 1.82 (1.21–2.73) 2.60 (1.72–3.95) 3.52 (2.32–5.35) 4.55 (2.87–7.20) <.0001
HR, hazard ratio; CI, conﬁdence interval; OS, overall survival
aHazard ratios at 9.5 months (median survival time)
bCreated by adding number of inﬂammatory markers with a value above the study population median
cP-trend calculated by entering inﬂammatory score as continuous variables in Cox proportional hazards model
dAdjusted for age at blood draw, gender, grade (well differentiated, moderately differentiated, poorly differentiated, undifferentiated, and unknown), stage (localized/
no evidence of disease, locally advanced, and metastatic), treatment status (naive, on, and post), number of metastatic sites, BMI (continuous) at blood draw and
physical activity (continuous)
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Table 5 Hazard ratiosa for death among selected patient subgroups
CRP IL-6 sTNF-RII MIC-1
>10mg/L vs. ≤ 10
mg/L
Q4 vs. Q1 Q4 vs. Q1 Q4 vs. Q1
HR (95% CI)b HR (95% CI)b HR (95% CI)b HR (95% CI)b
Agec
≤64.5 years 2.09 (1.53–2.86) 3.96 (2.48–6.33) 2.21 (1.41–3.45) 3.10 (1.96–4.90)
>64.5 years 2.00 (1.46–2.72) 1.78 (1.12–2.82) 2.18 (1.36–3.49) 2.41 (1.44–4.04)
P-interactiond 0.96 0.05 0.93 0.78
BMIc
≤25 kg/m2 2.83 (1.98–4.05) 4.70 (2.75–8.03) 2.52 (1.52–4.19) 2.56 (1.57–4.17)
>25 kg/m2 1.73 (1.23–2.31) 2.53 (1.60–4.00) 1.65 (1.10–2.49) 2.52 (1.60–3.96)
P-interactiond 0.03 0.12 0.12 0.49
Gender
Male 1.89 (1.40–2.55) 2.66 (1.74–4.07) 2.93 (1.90–4.51) 3.31 (2.10–5.24)
Female 2.44 (1.77–3.37) 3.22 (1.90–5.43) 1.41 (0.88–2.23) 2.40 (1.45–3.99)
P-interactiond 0.10 0.84 0.17 0.49
History of diabetes
No 1.91 (1.44–2.54) 2.93 (1.90–4.52) 1.67 (1.12–2.48) 2.06 (1.33–3.19)
Yes 2.65 (1.74–4.02) 4.25 (2.31–7.82) 3.27 (1.70–6.29) 5.20 (2.67–10.13)
P-interactiond 0.64 0.90 0.83 0.37
Metastatic disease
No 1.47 (0.95–2.27) 2.29 (1.18–4.47) 1.33 (0.74–2.39) 1.65 (0.93–2.93)
Yes 2.10 (1.59–2.76) 2.40 (1.58–3.66) 1.72 (1.13–2.62) 2.92 (1.88–4.53)
P-interactiond 0.15 0.29 0.96 0.11
Number of metastatic sitese
1 1.99 (1.42–2.79) 2.32 (1.37–3.92) 1.59 (0.93–2.72) 2.91 (1.75–4.84)
>1 2.05 (1.16–3.63) 2.44 (1.05–5.72) 1.70 (0.72–4.01) 6.41 (1.96–21.10)
P-interactiond 0.60 0.43 0.25 0.30
Grade
Well/moderately differentiated 2.42 (1.23–4.76) 2.41 (1.07–5.42) 3.77 (1.55–9.14) 2.82 (1.11–7.21)
Poorly differentiated/undifferentiated 2.56 (1.49–4.41) 5.20 (2.16–12.52) 2.30 (1.05–5.05) 3.23 (1.45–7.18)
P-interactiond 0.81 0.05 0.29 0.63
Smoking status
Never smokers 2.15 (1.52–3.03) 2.40 (1.47–3.93) 2.40 (1.51–3.82) 2.54 (1.52–4.23)
Ever smokers 1.99 (1.48–2.66) 3.43 (2.16–5.47) 1.73 (1.10–2.71) 2.93 (1.86–4.63)
P-interactiond 0.70 0.31 0.19 0.33
Regular aspirin usef
No 1.59 (1.05–2.41) 4.97 (2.55–9.70) 2.03 (1.04–3.96) 4.25 (2.03–8.91)
Yes 3.01 (1.91–4.75) 2.42 (1.32–4.45) 3.16 (1.68–5.94) 3.23 (1.62–6.43)
P-interactiond 0.001 0.34 0.35 0.62
Treatment statusg
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While differences in MIC-1 levels between PDAC
patients and healthy controls have previously been
reported16,38,39, little is known about the molecular
pathways underlying this association. Furthermore, it
was shown that both IL-640,41 and MIC-142 attenuate T-
cell-mediated anti-tumor immune response. In PDAC43,
as well as other cancers, MIC-1 overexpression is asso-
ciated with increased resistance to chemotherapy
drugs37. However, it is unlikely that resistance to treat-
ment explains the effect of MIC-1 in our study, since
there was no difference in survival in treatment naive or
on/post treatment group by MIC-1 levels (Table 5).
Our results carry multiple potential clinical and
translational implications. First, CRP, IL-6, and MIC-1
assays are inexpensive and non-invasive. Therefore, their
prognostic potential should be further investigated in
future studies. Furthermore, they could be used to
identify patients who may beneﬁt most from anti-
inﬂammatory strategies. Indeed, interest in the use of
circulating inﬂammatory cytokines as predictors of
treatment efﬁcacy was ﬁrst suggested by the RECAP
trial, a randomized phase II study of capecitabine with or
without ruxolitinib (JAK/STAT inhibitor) in patients
with refractory PDAC that showed a survival beneﬁt
with ruxolitinib in patients with high CRP or modiﬁed
GPS15. Unfortunately, subsequent phase III trials did not
conﬁrm this ﬁnding, but have led to research efforts in
other novel inﬂammation-mediated pathways, including
inhibitors of TBK1, which regulates a KRAS-driven
autocrine cytokine circuit44, immunomodulatory agents
such as CCR2 antagonists (ClinicalTrials.gov identiﬁer
NCT02732938), and vitamin D receptor VDR analogs,
which have been shown to reprogram the tumor
microenvironment45. It is conceivable that levels of
inﬂammatory cytokines may play a future role in helping
to select the patients who are most likely to beneﬁt from
these novel agents.
Advantages of our study include the prospective study
design, large number of patients, as well as detailed
information on clinical, pathological, treatment, and
lifestyle factors. We were also able to evaluate a variety
of inﬂammatory cytokines singly and in combination.
However, several limitations exist. We were not able to
evaluate pancreatic cancer-speciﬁc mortality, but 95% of
pancreatic cancer patients present with incurable dis-
ease at diagnosis, therefore it is highly unlikely that our
patients died of other causes. Furthermore, our study
consisted of predominantly white participants treated at
a tertiary academic center, and therefore our results may
not be generalizable to the overall population of pan-
creatic cancer patients. Reassuringly, though, the med-
ian survival of our study population is reﬂective of
PDAC patients overall. Finally, while circulating
inﬂammatory cytokines have the advantage of being
easily measurable and accessible in patients, plasma
levels may not adequately reﬂect inﬂammatory activity
within the tumor or its microenvironment. Fortunately,
recent technological advances that allow tumor RNA
sequencing in bulk or on single-cell populations will
pave the way toward elucidating the exact origin and
mechanism of the high-inﬂammatory state of PDAC
patients.
In conclusion, increasing levels of circulating inﬂam-
matory cytokines were associated with signiﬁcantly
decreased survival of patients with pancreatic cancer in
this large prospective clinic-based study. The potential
Table 5 continued
CRP IL-6 sTNF-RII MIC-1
>10mg/L vs. ≤ 10
mg/L
Q4 vs. Q1 Q4 vs. Q1 Q4 vs. Q1
HR (95% CI)b HR (95% CI)b HR (95% CI)b HR (95% CI)b
Treatment naive 2.08 (1.52–2.84) 2.88 (1.84–4.51) 1.70 (1.09–2.64) 2.02 (1.28–3.18)
On/post treatment 2.14 (1.54–2.95) 2.97 (1.82–4.83) 2.29 (1.44–3.64) 2.81 (1.63–4.82)
P-interactiond 0.43 0.72 0.60 0.54
CRP, C-reactive protein; IL-6, interleukin-6; MIC-1, macrophage inhibitory cytokine-1; sTNF-RII, tumor necrosis factor receptor 2; HR, hazard ratio; CI, conﬁdence interval;
BMI, body mass index
aHazard ratios at 9.5 months (median survival time)
bAdjusted for age at blood draw, gender, grade, (well differentiated, moderately differentiated, poorly differentiated, and unknown), stage (localized/no evidence of
disease, locally advanced, and metastatic), treatment status (naive, on treatment, and post treatment), number of metastatic sites, BMI (continuous) at blood draw,
physical activity (continuous), and excluding the stratifying variable
cMedian population values
dP-interaction was calculated by entering a cross-product term of stratifying variable and inﬂammatory cytokine (quartiles) into Cox proportional hazards model
eAmong patients with metastatic disease
fRegular use is deﬁned as intake frequency of ≥3 days/week
gRestricted to metastatic patients
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prognostic value of these markers, as well as their utility
for patient selection for novel anti-inﬂammatory and
immunomodulatory agents, should be evaluated in future
studies. Moreover, efforts to understand the pathogenesis
of the high-inﬂammatory state and development of novel
agents to decrease inﬂammation in PDAC patients are
warranted.
Study Highlights
What is current knowledge
● Inﬂammation and inﬂammatory conditions have
been associated with increased risk of pancreatic
cancer
● Individual inﬂammatory cytokines have been
associated with survival of pancreatic cancer
patients
What is new here
● The effect of inﬂammatory cytokines on pancreatic
cancer patient survival is mutually independent and
additive, suggesting that multiple inﬂammatory
pathways are involved in PDAC progression
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